Biotechnology: Co-Founder: Biontech will continue to be an independent company in the future



Co-founders: Biontech will remain an independent company in the future

According to CEO and co-founder Ugur Sahin, the biotech company will remain an independent company.

Photo: DPA

The owners of the company want Ugur Sahin Biotech to grow step by step. The corona vaccine manufacturer differs from the large pharmaceutical companies in the world in one important respect.

Mainz. According to company boss Ugur Sahin, Biotech, the company that produces the corona vaccine, should remain independent.

“There is no reason for me to believe otherwise,” he told the “Handelsblatt” (Monday). Ultimately, it is a question of the major shareholders. He himself assumes that he will remain one of the main shareholders of the company he co-founded. “I have no intention of selling shares.

Sahin did not rule out larger acquisitions. Ultimately, however, the question always remains as to whether the purchase of another company will help Biontech. “Just as we built Biontech bit by bit in the early stages, we now want to let the company grow step by step,” he said.

Biontech differs from the big pharmaceutical companies in the world in that it develops its own technology. There is no other way, because the mRNA technology, which is used in the corona vaccine, for example, has not been on the market for long. “Our superpower is not a global distribution network, our superpower is the power of innovation,” Sahin said.

Biotechnology is a very difficult business. Not only in the United States, but competition has increased significantly, Sahin said. “As a scientist, you wouldn’t research a discovery alone for long; you have to assume that the discovery was made somewhere else,” he explains. However, it promotes scientific exchange and innovation as well as competition.

© dpa-infocom, dpa:220613-99-646824/2



Please enter your comment!
Please enter your name here